Avalyn Pharma INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Novo Holdings A/S has reported beneficial ownership of 3,883,289 shares, representing 8.8% of Avalyn Pharma Inc.'s common stock.
NASDAQ
Norwest Venture Partners XV, LP, along with affiliated entities and individuals, has reported a beneficial ownership of 5.1% of Avalyn Pharma Inc.'s common stock as of June 30, 2026.
NASDAQ
FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 13.2% of Avalyn Pharma Inc.'s common shares as of June 30, 2026.